Tryngolza
Tryngolza (olezarsen) is a prescription antisense oligonucleotide medication used to reduce very high triglyceride levels in adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder. It works by targeting and reducing the production of apolipoprotein C-III (apoC-III), a protein that normally slows down the body's ability to break down triglycerides in the blood.
Tryngolza is an injectable antisense medication that lowers extremely high triglycerides in patients with familial chylomicronemia syndrome by reducing apoC-III protein production.
Key facts at a glance
- RxNorm
- 2701424
- Generic
- Tryngolza
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Tryngolza is indicated for the treatment of familial chylomicronemia syndrome (FCS) in adults, a rare genetic condition characterized by severely elevated triglyceride levels (often exceeding 880 mg/dL) that can lead to recurrent pancreatitis and other complications.
Tryngolza is an antisense oligonucleotide that specifically binds to and degrades messenger RNA (mRNA) for apolipoprotein C-III (apoC-III). By reducing apoC-III production in the liver, the medication enhances the activity of lipoprotein lipase, which helps clear triglyceride-rich lipoproteins (chylomicrons) from the bloodstream more efficiently.
Tryngolza is administered as a subcutaneous injection, typically once monthly. Common side effects may include injection site reactions, fatigue, and arthralgia. Patients should have their triglyceride levels monitored regularly during treatment. This medication is not a substitute for dietary fat restriction in FCS patients and should be used as part of a comprehensive management plan. Safety in pregnancy has not been established.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy